Labcorp Q4 EPS Beats Estimates by 3%, Revenue Falls Short, Issues FY2026 Guidance
Labcorp reported fourth-quarter adjusted EPS of $4.07 beating estimates by 12 cents, while revenue of $3.52 billion fell short of the $3.55 billion consensus. The company posted full-year EPS of $10.46 on $13.95 billion revenue and guided FY2026 EPS of $17.55–$18.25 with $14.61–$14.79 billion in sales.
1. Fourth-Quarter Results
Labcorp reported a GAAP profit of $164.7 million for Q4, translating to $1.98 per share. Adjusted earnings were $4.07 per share, exceeding analyst forecasts of $3.95, while revenue of $3.52 billion missed the $3.55 billion target.
2. Full-Year Performance
For the fiscal year, Labcorp delivered net income of $876.5 million, or $10.46 per share, on revenue of $13.95 billion. These figures mark a continuation of stable profitability and reflect demand across its diagnostics and drug development services.
3. FY2026 Guidance
The company issued full-year guidance of $17.55 to $18.25 EPS on revenue between $14.61 billion and $14.79 billion. This outlook implies mid-single-digit growth in both earnings and sales, driven by expansions in testing volumes and acquisitions.